

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	AIIY. S DOCKET: NOZAKI=8.1A
In re Application of:) Confirmation No. 3949
Masako NOZAKI) Art Unit: 1614
Appln. No.: 10/721,742) Examiner:
Filed: November 26, 2003) Washington, D.C.
For: METHOD OF TREATING OR INHIBITING THE DEVELOPMEN' OF BRAIN INFLAMMATION AND SERSIS	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:
- [X] B. before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

In re Appln. No. 10/721,742

- 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.
- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. Other information being provided for the examiner's consideration follows:

Attached hereto is a Partial European Search Report.

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:

Allen C. Yun Reg. No. 37,971

ACY:pp

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197
Facsimile: (202)737-3528
G:\BN\N\noza\nozaki8.1A\pto\2nd - IDS.doc

Substitute for form 1449A/PTO		Complete if Known						
				Application Number	10/721,742	10	TP	E
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 26, 2003	/		·		
		First Named Inventor	Masako NOZAKI					
		Group Art Unit	1614	2 APR	0 7	2004		
		Examiner Name		<u>a</u>				
Sheet	1	of	1	Attorney Docket Number	NOZAKI=8.1A	₹.		245
		•				W	4DE	MP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, er Cite No. 1 magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or cour published						
	AC	XP-001184701 – ABSTRACT , HIRABAYASHI et al., Cysteinyl leukotrienes activate microglia through the CYSLT1 receptor, Society for Neuroscience, 27(1)1160 (Nov. 10, 2001).					
.,							
Exami	ner	Date					
Signat	ure	Considered					

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.